阿托伐他汀联合川芎嗪注射液治疗慢性阻塞性肺疾病加重期的临床研究

目的 探讨阿托伐他汀联合川芎嗪注射液治疗慢性阻塞性肺疾病（COPD）加重期的临床疗效.方法 选择86例COPD急性加重期兼瘀血症患者,随机分为观察组和对照组,各43例,对照组采用常规治疗加阿托伐他汀,观察组在对照组基础上用川芎嗪注射液,观察两组患者血清白介素（IL）-6、IL-8、肿瘤坏死因子（TNF-α）水平及肺功能指标的改变情况及临床疗效.结果 治疗后6个月,观察组IL-6、IL-8、TNF-α水平分别为（27.3-3.6） ng/L、（1.3±0.3） ng/L、（16.9±3.4）ng/L,明显低于对照组[（33.9±3.4）ng/L、（1.6±0.2）ng/L、（23.1±3.9）ng/L]（P＜0.05）;观察组FVC、FEV1、FEV 1/FVC分别为（2.6±0.2）L、（1.3±0.3）L、（88.5±9.8）％,改善程度明显优于对照组[（2.4±0.2）L、（1.5±0.4）L、（83.2±9.3）％]（P＜0.05）;观察组总有效率为97.7％优于对照组（88.4％）;两组无不良反应发生.结论 阿托伐他汀联合川芎嗪注射液治疗痰热阻肺型COPD急性加重期能更有效的控制肺组织炎症反应,改善肺功能,从而提高临床疗效,且安全可靠.

Clinical study on atorvastatin combined with ligustrazine injection in treating exacerbations of chronic obstructive pulmonary disease

Objective To investigate the clinical efficacy of atorvastatin combined with ligustrazine injection in treating exacerbations of chronic obstructive pulmonary disease （COPD）.Methods 86 cases of patients with acute exacerbation of COPD and blood stasis were selected and randomly divided into observation group and control group,with 43 cases in each group,control group was treated with conventional therapy combined with atorvastatin,observation group was treated with ligustrazine injection based on control group,and the clinical efficacy,lung function index and serum IL-6,IL-8,TNF-α levels were observed between two groups.Results After 6 months of treatment,the IL-6,IL-8,TNF-α levels in observation group were （27.3 ± 3.6） ng/L,（1.3 ± 0.3） ng/L and （16.9 ± 3.4） ng/L respectively,significantly lower than those in control group [（33.9 ± 3.4） ng/L,（1.6 ± 0.2） ng/L,（23.1 ± 3.9） ng/L]（P 〈 0.05）; the FVC,FEV1,FEV1/FVC （%） in observation group were （2.6 ± 0.2） L,（1.3 ± 0.3） L and （88.5 ± 9.8）% respectively,improving more significantly than those in control group [（2.4 ± 0.2） L,（1.5 ±-0.4） L,（83.2 ± 9.3）%] （P 〈 0.05）; the total effective rate in observation group was 97.7%,better than that in control group （88.4%）; two gronps had no adverse reactions.Conclusion Atorvastatin combined with ligustrazine injection in treating acute exacerbation of COPD and blood stasis can make lung tissue inflammation control more effective,improve lung function,so as to improve clinical efficacy,which provides safety and reliability.